Select Language
CNR1
CNR1 Overview
| English Name | Cannabinoid CB1 receptor | Approved Drugs | 2 |
| Drugs in Clinical Trials | 33 | Target Synonym | Cannabinoid Receptor 1 (Brain)，CNR1，Cannabinoid Receptor 1，CANN6，CB-R，CNR，CB1，Central Cannabinoid Receptor，CB1K5，CB1A，CB1R，Receptor， Cannabinoid， CB1 |
| Highest Development Stage | Approved | ||
| English Name | Cannabinoid CB1 receptor |
| Target Synonym | Cannabinoid Receptor 1 (Brain)，CNR1，Cannabinoid Receptor 1，CANN6，CB-R，CNR，CB1，Central Cannabinoid Receptor，CB1K5，CB1A，CB1R，Receptor， Cannabinoid， CB1 |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 33 |
| Highest Development Stage | Approved |
CNR1 Product List
- Product Category
Protein (3)
- Product Status
Launched (3)
- Species
Human (3)
- Tag
- (1)His Tag & Flag Tag (1)His Tag & Avi Tag & Flag Tag (1)
- Conjugate
Unconjugated (2)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
CN1-H52P6 |  Human | HEK293 | Human CNR1 Full Length Protein (VLP) |  | ||
CN1-H55D3 | Human | InsectCells | Human CNR1 Protein, Flag,His Tag (Detergent) |  |  | |
CN1-H85D3 | Human | InsectCells | Biotinylated Human CNR1 Protein, Flag Tag&His,Avitag™ (Detergent) | | |
Total: 3
- 1
CNR1 Background
This gene encodes one of two cannabinoid receptors. The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene. [provided by RefSeq, May 2009]
CNR1 Synonyms
CNR1,cannabinoid receptor 1,CANN6, CB-R, CB1, CB1A, CB1K5, CB1R, CNR
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotechnologies Inc | Neoplasms; Nutrition Disorders; Child Nutrition Disorders; Vomiting; Nausea; Cachexia; Sarcopenia; Anorexia Nervosa | Details | |
| Cannabidiol soft-gel (Avecho Biotechnology) | CBD-TPM | Phase 3 Clinical | Sleep Initiation and Maintenance Disorders | Details | |
| Adezunap | AP-707 | Phase 3 Clinical | CannaXan GmbH | Stroke; Peripheral Nerve Injuries; Diabetes Mellitus; Low Back Pain; Accidental Injuries; Diabetic peripheral neuropathy; Neuralgia; Back Pain; Phantom Limb; Multiple Sclerosis; Peripheral Nervous System Diseases; Brachial Plexus Neuropathies; Somatoform Disorders; Diabetic Neuropathies; Pain, Postoperative; Paraplegia; Chronic Pain; Brain Injuries, Traumatic; Pain | Details |
| Dronabinol（Vertanical） | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | Details |
| cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Coronavirus Disease 2019 (COVID-19); Pericarditis; Cardiovascular Diseases; Myocarditis | Details | |
| V-24343 | V-24343; ANEB-001 | Phase 2 Clinical | Vernalis Plc | Poisoning; Obesity | Details |
| 11C-MePPEP | 11C-MePPEP | Phase 2 Clinical | Eli Lilly And Company | Substance-Related Disorders; Obesity | Details |
| AX-1602 | AX-1602 | Phase 2 Clinical | Axim Biotechnologies Inc | Psoriasis; Dermatitis, Atopic; Vitiligo | Details |
| Nimacimab | RYI-018; RYI-028; JNJ-2463 | Phase 2 Clinical | Bird Rock Bio Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Renal Insufficiency, Chronic; Diabetic Gastroparesis | Details |
| ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Weight Loss; Pain; Anorexia; Cachexia; Low Back Pain | Details |
| AEF-0217 | AEF-0217 | Phase 2 Clinical | Aelis Farma | Down Syndrome | Details |
| Monlunabant | S-MRI-1891; (-)-MRI-1891; NN9440–INV-202; INV-202; MRI-1891 | Phase 2 Clinical | Inversago Pharma Inc | Metabolic Syndrome; Metabolic Diseases; Diabetic Nephropathies; Obesity | Details |
| Cannabidiol Oral Solution (Benuvia Therapeutics/Radius Health) | RAD-011 | Phase 2 Clinical | Insys Therapeutics Inc | Seizures; Pain; Lennox Gastaut Syndrome; Epilepsy, Absence; Spasms, Infantile; Prader-Willi Syndrome; Epilepsies, Myoclonic | Details |
| C20T5 | C20T5 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| C12T12 | C12T12 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| Tetrahydrocannabinol valine hemisuccinate (Skye Bioscience) | NB-1111; Sb-100 OE; SBI-100 OE; THC-VHS-NEC; THCVHS; SBI-100; THCVHS-N; UM-5050; THCVHS-NE | Phase 2 Clinical | University Of Mississippi | Glaucoma, Open-Angle; Glaucoma; Ocular Hypertension | Details |
| IGC-AD1 | IGC-AD1 | Phase 2 Clinical | University Of South Florida | Dementia; Psychomotor Agitation; Alzheimer Disease | Details |
| AEF-0117 | AEF-0117 | Phase 2 Clinical | National Institute On Drug Abuse, Aelis Farma | Marijuana Abuse | Details |
| [11C]OMAR | [11C]JHU-75528 | Phase 1 Clinical | Johns Hopkins University School Of Medicine | Schizophrenia; Marijuana Abuse | Details |
| ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Neuralgia; Fibromyalgia | Details |
| Tetrahydrocannabivarin | GWP-42004; THCV; O-4394; DELTA9-THCV; GW-42004 | Phase 1 Clinical | Gw Pharmaceuticals Plc | Diabetes Mellitus, Type 2; Metabolic Syndrome; Obesity, Morbid; Hypercholesterolemia; Hyperglycemia; Dyslipidemias | Details |
| Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 1 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | Details |
| Zevaquenabant | MRI-1867; (S)-MRI-1867; INV-101 | Phase 1 Clinical | National Institutes Of Health | Scleroderma, Systemic | Details |
| Atorvastatin Calcium Hydrate/Cannabidiol | Phase 1 Clinical | Indication Bioscience LLC | Coronary Disease; Dyslipidemias | Details | |
| TPT0301 | TPT-0301; TPT0301 | Phase 1 Clinical | Tetra Pharm Technologies ApS | Chronic Pain | Details |
| INV-347 | NN9441; NN-9441; INV-347 | Phase 1 Clinical | Inversago Pharma Inc | Obesity | Details |
| IPI 201（Isosceles Pharmaceuticals Inc ） | IPI-201 | Phase 1 Clinical | Pain, Postoperative | Details | |
| GFB-024 | Phase 1 Clinical | Takeda Pharma | Kidney Diseases; Endocrine System Diseases; Diabetes Complications; Diabetic Nephropathies; Diabetes Mellitus | Details | |
| DBPR-211 | Phase 1 Clinical | National Health Research Institutes | Diabetes Mellitus, Type 2 | Details | |
| MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | Details |
| MP-20X | MP-20X | Clinical | Medipure Holdings | Mood Disorders; Anxiety Disorders | Details |
| Cannabidiol (Receptor Life Sciences) | Clinical | Receptor Life Sciences Inc | Autism Spectrum Disorder | Details | |
| Cannabidiol/Palmitoylethanolamide | THX-210; SCI–210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cannabidiol/Dronabinol | PPP-011; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT; GW-1000; KL16-012; THC-5; delta-9-THC/CBD; MPL-001; MPL-005 | Approved | Gw Pharmaceuticals | Sativex, Qixleef, QIXLEEFTM | Canada | Cancer Pain; Neuralgia; Chronic Pain; Muscle Spasticity; Multiple Sclerosis | null | 2005-04-01 | Healthy Aging; Multiple Sclerosis; Neuralgia, Postherpetic; Urinary Bladder, Overactive; Tic Disorders; Muscle Spasticity; Neuromyelitis Optica; Acute Pain; Malnutrition; Huntington Disease; Reflex Sympathetic Dystrophy; Sciatica; Tourette Syndrome; Stress Disorders, Post-Traumatic; Osteoarthritis, Knee; Phobia, Social; Back Pain; Dementia; Arthritis, Psoriatic; Neuralgia; Hepatic Insufficiency; Agoraphobia; Renal Insufficiency, Chronic; Drug Resistant Epilepsy; Hidradenitis Suppurativa; Corticobasal degeneration; Low Back Pain; Social Behavior; Cerebral Palsy; Spinal Cord Injuries; Migraine Disorders; Peripheral Nervous System Diseases; Sleep Initiation and Maintenance Disorders; Substance-Related Disorders; Depressive Disorder, Major; Pain; Spasm; Marijuana Use; Cancer Pain; Agitation; Chronic Pain; Marijuana Abuse; Squamous Cell Carcinoma of Head and Neck; Genital Diseases, Male; Renal Insufficiency; Depression; Neoplasms; Neck Pain; Anorexia; Arthritis, Rheumatoid; Opioid-Related Disorders; Diabetic Neuro | Details |
| Cannabidiol | GWP-42003-P; LYT-310; BRCX-014; GWP-42003; RLS-103; BOL-DP-o-05; GW-42003; BTX-1204; ZYN-002; PTL-101; CHI-902; APH-1501; AVCN-583601; GLA-015; BTX-1503; BTX-1801; BTX-1702; PBX-1308 | Approved | Gw Pharmaceuticals Plc | Epidiolex, Epidyolex, Zygel, Cannepil | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Peripheral Nervous System Diseases; Marijuana Smoking; Sleep Initiation and Maintenance Disorders; Facial Pain; Acne Vulgaris; HIV Infections; Tobacco Smoking; Substance-Related Disorders; Tobacco Use Cessation; Migraine Disorders; Ovarian Neoplasms; Schizophrenia; Marijuana Abuse; Rett Syndrome; Pain; Tuberous Sclerosis; Alcoholic Intoxication; Seizures; Chronic Pain; Inflammatory Bowel Diseases; Anxiety; Child Behavior Disorders; Marijuana Use; Autism Spectrum Disorder; Fatty Liver; Spinal Cord Injuries; Appetitive Behavior; Brain Injuries, Traumatic; Diabetes Mellitus, Type 2; Depression; Neoplasms; Musculoskeletal Pain; Opioid-Related Disorders; Bipolar Disorder; Coronavirus Disease 2019 (COVID-19); Dyspepsia; Psychotic Disorders; Hyperalgesia; Dysmenorrhea; Sturge-Weber Syndrome; Graft vs Host Disease; Brain Diseases; Blepharospasm; Sleep Wake Disorders; Pancreatic Neoplasms; Muscle injury; Anxiety Disorders; Hoarding Disorder; Arthritis, Rheumatoid; Diabetic Neuropathies; Chronic Urticaria; Schizophreni | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland